Literature DB >> 10775603

Functional differences between human and bovine immunodeficiency virus Tat transcription factors.

H P Bogerd1, H L Wiegand, P D Bieniasz, B R Cullen.   

Abstract

Transcriptional transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) promoter element by the essential viral Tat protein requires recruitment of positive transcription elongation factor b (P-TEFb) to the viral TAR RNA target. The recruitment of P-TEFb, which has been proposed to be necessary and sufficient for activation of viral gene expression, is mediated by the highly cooperative interaction of Tat and cyclin T1, an essential component of P-TEFb, with the HIV-1 TAR element. Species, such as rodents, that encode cyclin T1 variants that are unable to support TAR binding by the Tat-cyclin T1 heterodimer are also unable to support HIV-1 Tat function. In contrast, we here demonstrate that the bovine immunodeficiency virus (BIV) Tat protein is fully able to bind to BIV TAR both in vivo and in vitro in the absence of any cellular cofactor. Nevertheless, BIV Tat can specifically recruit cyclin T1 to the BIV TAR element, and this recruitment is as essential for BIV Tat function as it is for HIV-1 Tat activity. However, because the cyclin T1 protein does not contribute to TAR binding, BIV Tat is able to function effectively in cells from several species that do not support HIV-1 Tat function. Thus, BIV Tat, while apparently dependent on the same cellular cofactor as the Tat proteins encoded by other lentiviruses, is nevertheless unique in terms of the mechanism used to recruit the BIV Tat-cyclin T1 complex to the viral LTR promoter.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10775603      PMCID: PMC111987          DOI: 10.1128/jvi.74.10.4666-4671.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation.

Authors:  R Taube; K Fujinaga; J Wimmer; M Barboric; B M Peterlin
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

2.  Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product.

Authors:  S Y Kao; A F Calman; P A Luciw; B M Peterlin
Journal:  Nature       Date:  1987 Dec 3-9       Impact factor: 49.962

3.  Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription.

Authors:  P D Bieniasz; T A Grdina; H P Bogerd; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

4.  Use of eukaryotic expression technology in the functional analysis of cloned genes.

Authors:  B R Cullen
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

5.  A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation.

Authors:  S Roy; U Delling; C H Chen; C A Rosen; N Sonenberg
Journal:  Genes Dev       Date:  1990-08       Impact factor: 11.361

6.  Functional comparison of transactivation by simian immunodeficiency virus from rhesus macaques and human immunodeficiency virus type 1.

Authors:  G A Viglianti; J I Mullins
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

7.  Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.

Authors:  M Kuppuswamy; T Subramanian; A Srinivasan; G Chinnadurai
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

8.  A novel genetic system to detect protein-protein interactions.

Authors:  S Fields; O Song
Journal:  Nature       Date:  1989-07-20       Impact factor: 49.962

9.  Trans-activation of human immunodeficiency virus occurs via a bimodal mechanism.

Authors:  B R Cullen
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

10.  The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1.

Authors:  M Emerman; M Guyader; L Montagnier; D Baltimore; M A Muesing
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  11 in total

1.  Analysis of cellular factors that mediate nuclear export of RNAs bearing the Mason-Pfizer monkey virus constitutive transport element.

Authors:  Y Kang; H P Bogerd; B R Cullen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.

Authors:  Baode Xie; Valerie Calabro; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  The human endogenous retrovirus K Rev response element coincides with a predicted RNA folding region.

Authors:  J Yang; H Bogerd; S Y Le; B R Cullen
Journal:  RNA       Date:  2000-11       Impact factor: 4.942

4.  Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes.

Authors:  Juan Martin-Serrano; Kelvin Li; Paul D Bieniasz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells.

Authors:  Koh Fujinaga; Dan Irwin; Ran Taube; Fan Zhang; Matthias Geyer; B Matija Peterlin
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Structure-based design of a dimeric RNA-peptide complex.

Authors:  D M Campisi; V Calabro; A D Frankel
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

7.  Molecular basis of the internalization of bovine immunodeficiency virus Tat protein.

Authors:  Gang Deng; Yang Su; Junjie Mu; Rina Sha; Yunqi Geng; Wentao Qiao; Qimin Chen
Journal:  Virus Genes       Date:  2007-10-19       Impact factor: 2.332

8.  A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.

Authors:  Hal P Bogerd; Brian P Doehle; Heather L Wiegand; Bryan R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

9.  Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference.

Authors:  Glen A Coburn; Bryan R Cullen
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Replication of human immunodeficiency viruses engineered with heterologous Tat-transactivation response element interactions.

Authors:  Baode Xie; Mark A Wainberg; Alan D Frankel
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.